WANDERLEY MARQUES BERNARDO

(Fonte: Lattes)
Índice h a partir de 2011
28
Lattes
Projetos de Pesquisa
Unidades Organizacionais
FMUSP, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/47 - Laboratório de Hepatologia por Vírus, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Colaboração internacional: Itália ×

Resultados de Busca

Agora exibindo 1 - 3 de 3
  • article 14 Citação(ões) na Scopus
    Ga-68-Prostate-specific membrane antigen (PSMA) positron emission tomography (pet) in prostate cancer: a systematic review and meta-analysis
    (2021) MATUSHITA, Cristina S.; SILVA, Ana M. Marques da; SCHUCK, Phelipi N.; BARDISSEROTTO, Matteo; PIANT, Diego B.; PEREIRA, Jonatas L.; CERCI, Juliano J.; COURA-FILHO, George B.; ESTEVES, Fabio P.; AMORIM, Barbara J.; V, Gustavo Gomes; BRITO, Ana Emilia T.; BERNARDO, Wanderley M.; MUNDSTOCK, Eduardo; FANTI, Stefano; MACEDO, Bruna; ROMAN, Diego H.; TEM-PASS, Cinthia Scatolin; HOCHHEGGER, Bruno
    Introduction: Prostate cancer (PC) is the second most commonly diagnosed cancer in males. Ga-68-PSMA PET/CT, a non-invasive diagnostic tool to evaluate PC with prostate-specific membrane antigen (PSMA) expression, has emerged as a more accurate alternative to assess disease staging. We aimed to identify predictors of positive Ga-68-PSMA PET and the accuracy of this technique. Materials and methods: Diagnostic accuracy cross-sectional study with prospective and retrospective approaches. We performed a comprehensive literature search on PubMed, Cochrane Library, and Embase database in search of studies including PC patients submitted to radical prostatectomy or radiotherapy with curative intent and presented biochemical recurrence following ASTRO 1996 criteria. A total of 35 studies involving 3910 patients submitted to 68-Ga-PSMA PET were included and independently assessed by two authors: 8 studies on diagnosis, four on staging, and 23 studies on restaging purposes. The significance level was alpha=0.05. Results: pooled sensitivity and specificity were 0.90 (0.86-0.93) and 0.90 (0.82-0.96), respectively, for diagnostic purposes; as for staging, pooled sensitivity and specificity were 0.93 (0.86-0.98) and 0.96 (0.92-0.99), respectively. In the restaging scenario, pooled sensitivity and specificity were 0.76 (0.74-0.78) and 0.45 (0.27-0.58), respectively, considering the identification of prostate cancer in each described situation. We also obtained specificity and sensitivity results for PSA subdivisions. Conclusion: Ga-68-PSMA PET provides higher sensitivity and specificity than traditional imaging for prostate cancer.
  • article 4 Citação(ões) na Scopus
    Ten papers for teachers of evidence-based medicine and health care: Sicily workshop 2019
    (2021) NUNAN, David; LINDBLAD, Adrienne; WIDYAHENING, Indah S.; BERNARDO, Wanderley M.; CHI, Ching-Chi; COWDELL, Fiona; BECKER, Karen; CONSTANTINE, Shadia; EAST, Christine; MYRHAUG, Hilde T.; JOHNSON, Susanne Grodem; JACK, Edmund; THOMPSON, Rachel; ACHILLEOS, Haris; BERG, Rigmor C.; SNIBSOER, Anne Kristin; PUSCASIU, Lucian; BARTELINK, Marie-Louise E. L.; PEET, Petra G. van; BERTI, Franco; TILSON, Julie; TIKKINEN, Kari A. O.; ALBARQOUNI, Loai; HOEGEN, Peter
  • article 4 Citação(ões) na Scopus
    Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses
    (2022) PASSONE, Caroline de Gouveia Buff; GIANI, Elisa; VAIVRE-DOURET, Laurence; KARIYAWASAM, Dulanjalee; BERDUGO, Marianne; GARCIN, Laure; BELTRAND, Jacques; BERNARDO, Wanderley Marques; POLAK, Michel
    Objective In monogenic diabetes due to KCNJ11 and ABCC8 mutations that impair KATP- channel function, sulfonylureas improve long-term glycemic control. Although KATP channels are extensively expressed in the brain, the effect of sulfonylureas on neurological function has varied widely. We evaluated published evidence about potential effects of sulfonylureas on neurological features, especially epilepsy, cognition, motor function and muscular tone, visuo-motor integration, and attention deficits in children and adults with KCNJ11 and ABCC8-related neonatal-onset diabetes mellitus. Research Design and Methods We conducted a systematic review and meta-analyses of the literature (PROSPERO, CRD42021254782), including individual-patient data, according to PRISMA, using RevMan software. We also graded the level of evidence. Results We selected 34 of 776 publications. The evaluation of global neurological function before and after sulfonylurea (glibenclamide) treatment in 114 patients yielded a risk difference (RD) of 58% (95%CI, 43%-74%; I-2 = 54%) overall and 73% (95%CI, 32%-113%; I-2 = 0%) in the subgroup younger than 4 years; the level of evidence was moderate and high, respectively. EEG studies of epilepsy showed a RD of 56% (95%CI, 23%-89%; I-2 = 34%) in patients with KCNJ11 mutations, with a high quality of evidence. For hypotonia and motor function, the RDs were 90% (95%CI, 69%-111%; I-2 = 0%) and 73% (95%CI, 35%-111%; I-2 = 0%), respectively, with a high level of evidence. Conclusions Glibenclamide significantly improved neurological abnormalities in patients with neonatal-onset diabetes due to KCNJ11 or ABCC8 mutations. Hypotonia was the symptom that responded best. Earlier treatment initiation was associated with greater benefits.